Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
Bullboard Posts
User Avatar Image
(1507)
•••
Post by wildbird1on Mar 18, 2019 9:54am
102 Views
Post# 29499773

What could happen if...

What could happen if...I agree with posters that says GEN is not ready for a Big Pharma deal..yet.

To give you an idea to what could happen if GEN enter into a deal with a Big Pharma read the link below...
https://finance.yayoo.com/news/exact-sciences-pfizer-enter-u-100000808.html

As you can see exas:us wasn't taken over by a big pharma, NO, they just signed a deal until 2021.

The effect of this deal on the SP...
The deal was signed on Aug 22,2018 the SP jumped from $47USD to $80USD in the following weeks, then back down to $56USD in Dec 2018.

In the link Exas:us said (QUOTE) Under the agreement, pfizer will co-promote(and sell) Cologuard with Exas:us beginning in the fourth quarter of 2018(END of QUOTE).

In the fourth quarter of 2018 the SP jumped from $56USD to today $96USD (and still climbing)... could be because investors expect positive results from this deal in the next few financial.

Someday it will be GEN time for a deal with a Big Pharma.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities